SEI Investments
SVA

SEI Investments’s Sinovac Biotech, Ltd SVA Stock Holding History

SEI Investments’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1
Closed – – 3898
2018
Q2 		$0 Buy
+1
New +$8 ﹤0.01% 4009
2018
Q1 		– Sell
-17
Closed – – 3897
2017
Q4 		$0 Buy
+17
New +$127 ﹤0.01% 3690

Other funds holding SVA

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SSP
Sapphire Star Partners Redmond, Washington $74.7M AUM 5.87% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $120M AUM 52.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return

SEI Investments's SVA Position: Q3 2018 in Review

SEI Investments sold out of Sinovac Biotech, Ltd (SVA) in Q3 2018, closing a stake of 1 share.

SEI Investments first reported a position in SVA in Q4 2017 and held it in 2 quarters. The position peaked at $0 in Q2 2018. 28 funds tracked by Wall St. Rank hold SVA as of Q3 2018.

  • SEI Investments reported no remaining Sinovac Biotech, Ltd position as of Q3 2018 after selling out during the quarter.
  • SEI Investments sold 1 Sinovac Biotech, Ltd share in Q3 2018.
  • SEI Investments first reported a position in Sinovac Biotech, Ltd in Q4 2017 and held it in 2 quarters.
  • SEI Investments's Sinovac Biotech, Ltd position peaked at $0 in Q2 2018.
  • 28 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q3 2018.

Based on SEI Investments's 13F filing for Q3 2018, filed 8 Nov 2018.